Iovance Biotherapeutics, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in San Carlos, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $264 million and a loss of $391 million (its filed statements).
Product businessBiological Products, (No Diagnostic Substances)San Carlos, CAfilings since 20087 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2836, Biological Products, (No Diagnostic Substances)); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.0 out of ten, 7 of 9 metrics filed and 2 estimated: past 6.8 out of ten, present 6.1 out of ten, future 5.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 5.8 out of ten. 1 warning event since 2017; the latest 2021-03-12. 58th percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 9.4 out of ten. +1385.9% a year over 3 filed years; profit years unseen. 94th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 2.8 out of ten. CrossAssetData estimate 2.8/10, confidence 35 of 100 (one part). 28th percentile among 146 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 4.9 out of ten. ROE -56%: lost 56¢ per shareholder dollar. Leverage 23%: owes 23¢ per asset dollar. 49th percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 7.9 out of ten. top 21% of 102 in its family; net margin -148.4%. 79th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 6.0 out of ten. top 40% of 108 in its family for leadership; chief executive since 2021. 60th percentile among 108 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 3.7 out of ten. bottom 37% of 92 in its family for room to expand. 37th percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.7 out of ten. top 34% of 100 in its family for growth drivers. 66th percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 73 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 10-K filed 2026-02-24 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 8-K, 2026-10-05. Filings on record since 2008. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Amtagvi 84%, Proleukin 17%. By geography: United States 98%, Outside the United States 2%. As tagged in its annual report (Form 10-K, filed 2026-02-24).
Who runs it
Vogt, Frederick G (Interim CEO & General Counsel); Roche, Corleen M. (Chief Financial Officer); Bilinsky, Igor (Chief Operating Officer); Berkowitz, Noah (Chief Medical Officer); Puri, Raj K. (Chief Regulatory Officer); Kirby, Daniel Gordon (Chief Commercial Officer); Graf, Finckenstein Friedrich (Chief Medical Officer); Rosinack, Matthew W. (SVP, Finance (Int. PFO & PAO)); Countouriotis, Athena (director); Dukes, Iain D. (director); and 2 more. 12 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-02.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.